ACADIA Pharmaceuticals has entered into a joint venture and license agreement with Neuren Pharmaceuticals to commercialise and develop trofinetide and Neuren's development candidate NNZ-2591. ACADIA will make an initial upfront payment of $100 million to Neuren, alongside future milestone payments that can potentially total up to $405 million for each product.